Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Completed
- Conditions
- Oral Squamous Cell Carcinoma (OSCC)
- Registration Number
- NCT07015333
- Lead Sponsor
- Commonwealth Healthcare Corporation
- Brief Summary
Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- Advanced betel nut-induced oral cancer
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective Response Rate (ORR) From date first treatment received until 3 months later Assessed by clinical measurement of largest tumor size
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHCC
🇲🇵Saipan, Northern Mariana Islands